Note: As of Sept 14, 2026, Dr. Boehm has taken on a new role as Executive Director, Global Research Strategy, Amgen.
Over the last decade, Dr. Boehm has led a research group at the Broad Institute and MIT’s Koch Institute focused on bringing the power of functional genomics to bear on living samples from cancer patients with particular emphasis on rare and underrepresented tumors. The team partners with patients across the country, enabling them to donate living tissue for research, creates organoid and cell models and leverages these living tissues to make precision functional genomics possible for individual cancer patients. Dr. Boehm also served as the SVP and Chief Science Officer of Break Through Cancer, a novel foundation dedicated to reimagining solutions for cancer by harnessing the power of extraordinary partnerships.
Break Through Cancer unites leading cancer institutions jointly focused on overcoming barriers impossible for any single organization to solve leveraging the pillars of "radical collaboration." Before transitioning to MIT and Break Through Cancer, Dr. Boehm previously spent 14 years in the Broad Institute’s Cancer Program, most recently as an Institute Scientist and Scientific Director of the Cancer Dependency Map project. As the Director of the Broad’s Cancer Model Development Center (part of the National Cancer Institute’s Human Cancer Models Initiative), he led his laboratory in developing a scalable capacity to convert patient tumors into organoids and other cell models.
Jesse received his BS in biology from MIT and his PhD from Harvard University, Division of Medical Sciences at Dana-Farber Cancer Institute.
